Efficacy of Levodopa/Carbidopa intestinal gel (LCIG) on motor and sensory abnormalities in patients with Parkinson's Disease

Trial Profile

Efficacy of Levodopa/Carbidopa intestinal gel (LCIG) on motor and sensory abnormalities in patients with Parkinson's Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Nov 2016 New trial record
    • 14 Oct 2016 Results published in the Clinical Neuropharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top